<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00801710</url>
  </required_header>
  <id_info>
    <org_study_id>200-0001</org_study_id>
    <nct_id>NCT00801710</nct_id>
  </id_info>
  <brief_title>CrossBoss and Stingray Catheter and Entera Guidewire Chronic Total Occlusion (CTO) Study</brief_title>
  <official_title>CrossBoss and Stingray Catheter and Entera Guidewire Chronic Total Occlusion (CTO) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BridgePoint Medical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to determine if the BridgePoint Medical System (CrossBoss Catheter, Stingray&#xD;
      Catheter, Entera Guidewire) can facilitate safe and effective placement of a guidewire in the&#xD;
      true lumen of coronary vessels distal to a chronic total occlusion (CTO).&#xD;
&#xD;
      The hypothesis is that the BridgePoint Medical System can do this without an increase in&#xD;
      major complications.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CTO Crossing Rate</measure>
    <time_frame>Peri-procedural</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perforation rate</measure>
    <time_frame>Peri-procedural</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute myocardial infarction (AMI)</measure>
    <time_frame>Peri-procedural</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Artery Chronic Total Occlusion</condition>
  <arm_group>
    <arm_group_label>BridgePoint Medial System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BridgePoint Medical System (CrossBoss Catheter, Stingray Catheter, Entera Guidewire)</intervention_name>
    <description>Revascularization of coronary artery chronic total occlusion.&#xD;
Use of the BridgePoint Medical System to cross coronary CTOs prior to definitive revascularization treatment via angioplasty and/or stent implant</description>
    <arm_group_label>BridgePoint Medial System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Suitable for coronary intervention&#xD;
&#xD;
          -  de novo or restenotic CTO at least 3 months old, in proximal or mid coronary artery&#xD;
             segment, 3.0-5.0 mm in diameter&#xD;
&#xD;
          -  Mild/moderate proximal vessel tortuosity&#xD;
&#xD;
          -  Mild/moderate lesion angulation&#xD;
&#xD;
          -  Mild/moderate calcification&#xD;
&#xD;
          -  Satisfactory distal vessel visualization&#xD;
&#xD;
          -  Mild/moderate side branch interference&#xD;
&#xD;
          -  19 years old&#xD;
&#xD;
          -  BMI&lt;40&#xD;
&#xD;
          -  LVEF&gt;20%&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Extensive dissection from guidewire manipulation&#xD;
&#xD;
          -  SVG or in-stent CTO&#xD;
&#xD;
          -  Aorto-ostial CTO&#xD;
&#xD;
          -  Unable to take aspirin, Clopidogrel, or Ticlopidine&#xD;
&#xD;
          -  Thrombus/vessel filling defects&#xD;
&#xD;
          -  Severe cerebrovascular disease/stroke within 1 month&#xD;
&#xD;
          -  Intervention within 2 weeks&#xD;
&#xD;
          -  Renal insufficiency&#xD;
&#xD;
          -  GI bleeding&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Life expectancy &lt;2 years&#xD;
&#xD;
          -  Significant anemia&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Severe electrolyte imbalance&#xD;
&#xD;
          -  Anaphylaxis to contrast&#xD;
&#xD;
          -  NYHA class IV&#xD;
&#xD;
          -  Unstable angina requiring intervention&#xD;
&#xD;
          -  MI within 2 weeks&#xD;
&#xD;
          -  Uncontrolled diabetes&#xD;
&#xD;
          -  Participating in another protocol&#xD;
&#xD;
          -  Unwilling/unable to comply with protocol&#xD;
&#xD;
          -  Angina/ischemia caused by target vessel&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Horst Sievert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CardioVascular Center Frankfurt, St. Katharinen Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Main Taunus Hospital</name>
      <address>
        <city>Bad Soden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Darmstadt</name>
      <address>
        <city>Darmstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CardioVascular Center Frankfurt, St. Katharinen Hospital</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäres Herz- und Gefässzentrum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 2, 2008</study_first_submitted>
  <study_first_submitted_qc>December 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2008</study_first_posted>
  <last_update_submitted>January 24, 2021</last_update_submitted>
  <last_update_submitted_qc>January 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

